

# MEDICINES CONTROL COUNCIL



## EXEMPTIONS FROM CERTAIN MEDICINE REGISTRATION REQUIREMENTS FOR HUMAN MEDICINES

This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control Council's current thinking on the safety, quality and efficacy of medicines. It is not intended as an exclusive approach. Council reserves the right to request any additional information to establish the safety, quality and efficacy of a medicine in keeping with the knowledge current at the time of evaluation. Alternative approaches may be used, but these should be scientifically and technically justified. The MCC is committed to ensure that all registered medicines will be of the required quality, safety and efficacy. It is important that applicants adhere to all administrative requirements to avoid delays in the processing and evaluation of applications.

Guidelines and application forms are available from the office of the Registrar of Medicines and the MCC website.

Version 1 published for comment	December 2017
Due date for comment	30 March 2018

**DR JC GOUWS**  
**REGISTRAR OF MEDICINES**

## TABLE OF CONTENTS

	Page
<b>1 INTRODUCTION</b> .....	<b>4</b>
<b>2 OBJECTIVES</b> .....	<b>5</b>
<b>3 DEFINITIONS</b> .....	<b>5</b>
3.1 Well-established APIs, API combinations and products (medicines) .....	5
<b>4 GENERAL REQUIREMENTS</b> .....	<b>6</b>
4.1 Letter of application .....	6
4.2 Application for registration.....	6
<b>5 SITUATIONS WHERE EXEMPTION FROM CERTAIN REQUIREMENTS MAY BE CONSIDERED.</b> .....	<b>6</b>
5.1 Transcription from MBR1 or MRF1 to ZA CTD .....	6
5.2 Medicines where limited clinical data and safety are available.....	7
5.3 Medicines that are well established but the moiety has not previously been registered in South Africa.....	7
5.4 Medicines where the innovator product is no longer marketed in South Africa .....	7
5.5 Medicines where the innovator product is no longer marketed in South Africa but for which there are pharmacopoeial monographs available .....	7
<b>6 UPDATE HISTORY</b> .....	<b>7</b>

**ABBREVIATIONS AND ACRONYMS**

Act	Medicines and Related Substances Act, 1965 (Act 101 of 1965, as amended)
API	Active Pharmaceutical Ingredient
CTD	Common Technical Document
IVD	<i>in vitro</i> diagnostic
MCC	Medicines Control Council
PBRER	Periodic Benefit Risk Evaluation Report
PSUR	Periodic Safety Update Report
RSA	Republic of South Africa
USA	United States of America

## 1 INTRODUCTION

The Medicines and Related Substances Act (Act 101 of 1965) (hereinafter 'the Act') makes provision for the registration of human medicines based on quality safety and efficacy.

Whilst the Act stipulates that only the safety, quality and therapeutic efficacy of a medicine may be considered to determine whether or not the registration or availability of a medicine is in the public interest, the Act does make provision for consideration of registration of medicines, or exemption from certain registration requirements or exemption from registration in special circumstances.

The relevant legislation includes the following provisions:

### **The Act:**

#### **Section 1(3)**

- 1.3 *In determining whether or not the registration or availability of a medicine is in the public interest, regard shall be had only to the safety, quality and therapeutic efficacy thereof in relation to its effect on the health of man or any animal, as the case may be.*

#### **Section 14(3)**

- (1) *Save as provided in this section or sections 21 and 22A, no person shall sell any medicine, medical device or IVD which is subject to registration by virtue of a declaration published in terms of subsection (2) unless it is registered.*
- (3) *In the case of a medicine, medical device or IVD which was available for sale in the Republic immediately prior to the date of publication in the Gazette of the declaration by virtue of which it is subject to registration in terms of this Act, the provisions of subsection (1) shall come into operation—*
- (a) *if no application for the registration of such medicine, medical device or IVD is made within the period of six months immediately succeeding that date, on the expiration of that period; or*
- (b) *if an application for the registration of such medicine, medical device or IVD is made within the said period, on the date one month after the date on which a notice in respect of such medicine, medical device or IVD is published in the Gazette in terms of section 15(9) or section 17(a).*

#### **Section 36** *Exclusion of any medicine, scheduled substance, medical device or IVD from operation of the Act*

- (1) *The Minister may, on the recommendation of the Authority, by notice in the Gazette exclude, subject to such conditions as he or she may determine, any medicine, Scheduled substance, medical device or IVD from the operation of any or all of the provisions of this Act, and may in like manner amend or withdraw any such notice.*
- (2) *Notwithstanding subsection (1), the exclusion of any medicine or Scheduled substance, from the operation of sections 18A and 22G shall be effected by the Minister on the recommendation of the Pricing Committee.*

### **Regulations made in terms of the Act:**

The following General Regulations issued in terms of the Act enable the Authority to stipulate the technical requirements for the registration of medicines for both human and veterinary use and ensure continued compliance with the accepted standards and specifications.

**Regulation 16(6)**

- (6) *A medicine, in respect of which an application for registration is made, must comply with the technical requirements as determined by the Authority.*

**Regulation 16(9)**

- (9) *The provisions of this regulation shall, with the necessary changes, apply to the application for the registration of veterinary medicines.*

**Regulation 53(1)**

- (1) *Every medicine must continue to comply with the standards and specifications which were furnished to the Authority and which have been accepted by the Authority with regard to such medicine.*
- (2) *Any proposed deviation from accepted standards and specifications referred to in sub-regulation (1) must be submitted to the Authority for prior approval and such deviation shall not be introduced before the said approval has been granted.*

Therefore, although South African law does not have specific enabling provisions for an "Orphan Drug" programme such as that applied in the USA, Europe or Australia, the possibility does exist to stipulate alternative requirements for medicines required by small patient populations (human).

**2 OBJECTIVES**

The objective of this guideline is to clarify the provisions of the Act that allow for exemptions from certain requirements and to encourage applicants to register much needed medicines for which the regulatory burden may be perceived as being too high.

**3 DEFINITIONS**

**3.1 Well-established APIs, API combinations and products (medicines)<sup>1</sup>**

APIs, API combinations and products, which

- have been marketed for at least five years in countries that undertake active post-marketing monitoring;
- have been widely used in a sufficiently large number of patients to permit the assumption that safety and efficacy are well known; and
- have the same route of administration and strength, and the same or similar indications as in those countries.

---

<sup>1</sup> This definition does not take into account possible sensitivities to excipients and other factors relevant to therapeutic equivalence.

## 4 GENERAL REQUIREMENTS

All applications for exemptions from requirements must be addressed to the Registrar of Medicines.

### 4.1 Letter of application

4.1.1 Indicate clearly in the letter of application:

- the requirement(s) for which exemption is required;
- justification for such exemption;
- where the relevant justification is located in the dossier.

4.1.2 At least the following should be addressed in the dossier:

- (i) Details of registration or pending registration of the medicine with any other regulatory authority, and the history of the medicine;
- (ii) Any sale in RSA;
- (iii) Known marketing experience in other countries;
- (iv) A description of the disease or condition for which the medicine is proposed to be used;
- (v) The basis for concluding that the medicine is:
  - in the interest of public health;
  - for use in a pandemic or high impact situation;
  - for an unmet clinical/health need; or
  - for a rare disease or condition.
- (vi) The size and other demographic characteristics of the patient population affected in RSA and the source of the information.
- (viii) The basis for concluding that alternative approaches may be used or requirements waived
- (ix) Confirmation that Periodic Safety Update Reports (PSUR) and/or Periodic Benefit Risk Evaluation Reports (PBRER) will be available on request.

### 4.2 Application for registration

The ZA CTD dossier format must be used for all applications for registration of human medicines.

## 5 SITUATIONS WHERE EXEMPTION FROM CERTAIN REQUIREMENTS MAY BE CONSIDERED.

### 5.1 Transcription from MBR1 or MRF1 to ZA CTD

Conversion of MBR1 or MRF1 to CTD requires transcription of the currently approved information to the ZACTD format. It is not necessary to populate those sections of the CTD (e.g. pharmaceutical development report) where information was not required at the time of submission of the original application, or for the registration of the medicine, or for subsequent amendments when these were applied for. Resubmission of non-clinical and clinical data (Annexures 13, 14 & 15 / PARTs 4 & 5) is not required when transcribing from MBR1 or MRF1 to CTD.

Refer to the communication to industry regarding the ZACTD implementation  
(9.74 ZACTD Implementation Jun16v1)

**5.2 Medicines where limited clinical data and safety are available**

Promising medicines, based on 4.1.2 (v), with limited clinical data in support of safety and efficacy may be considered provided that there is a prospectively planned process for the development of further supporting evidence (e.g. phase IV studies or patient registries).

**5.3 Medicines that are well established but the moiety has not previously been registered in South Africa.**

In such circumstances peer-reviewed published literature based evidence in support of the safety and efficacy could be considered.

In terms of quality, pharmacopoeial requirements, as well as compliance with the minimum requirements stipulated in the PA CTD guideline, could be considered. As no locally registered reference product would be available for comparison, the influence of the formulation on the release of the API may be demonstrated by comparison of the dissolution profiles prescribed of the test product and the unformulated API. Where a reference product can be obtained from a country, the regulatory authority of which the MCC aligns itself with, this product can be used for comparative studies.

**5.4 Medicines where the innovator product is no longer marketed in South Africa**

In such circumstances peer-reviewed published literature based evidence in support of the safety and efficacy could be considered.

In terms of quality, pharmacopoeial requirements, as well as compliance with the minimum requirements stipulated in the PA CTD guideline, could be considered. As stated in 5.3, the influence of the formulation on the release of the API may be demonstrated as no locally registered reference product would be available. Where a reference product can be obtained from a country, the regulatory authority of which the MCC aligns itself with, this product can be used for comparative studies.

Refer to the PA CTD guideline section 3.2.R.1 II regarding the choice of reference products.

**5.5 Medicines where the innovator product is no longer marketed in South Africa but for which there are pharmacopoeial monographs available**

In such circumstances peer-reviewed published literature based evidence in support of the safety and efficacy could be considered.

In terms of quality, pharmacopoeial requirements, as well as compliance with the minimum requirements stipulated in the PA CTD guideline, could be considered. As stated in 5.3, the influence of the formulation on the release of the API may be demonstrated as no locally registered reference product would be available. Where a reference product can be obtained from a country, the regulatory authority of which the MCC aligns itself with, this product can be used for comparative studies.

Refer to the PA CTD guideline section 3.2.R.1 II regarding the choice of reference products.

**6 UPDATE HISTORY**

Date	Reason for amendment	Version & Publication
Nov 2017	First publication for comment	v1, December 2017
30 March 2018	Deadline for comment	